Gregory M. McKee

GVIC Communications Corp. operates as an information and marketing solutions company. The firm engages in the provision of information and related services through print and digital media. It operates through following segments: Environmental and Property Information, Commodity Information and Community Media. The company was founded in 1990 and is headquartered in Vancouver, Canada.

Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX.

Formulation Technologies LLC operates as a contract manufacturer in the areas of pharmaceutical dosage form development. It specializes in controlled release and bioavailability enhancement technologies, such as hot melt extrusion, fluid bed processing, liquid filled capsules, and spray drying. The company was founded by Robert O. Williams III and is headquartered in Austin, TX.

Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada.

Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.

CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA.

San Diego Regional Economic Development Corp. operates as a non-profit organization. It mobilizes business, government, and civic leaders to maximize the region’s economic prosperity and global competitiveness. The company is headquartered in San Diego, CA.

Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company was founded on September 24, 2019 and is headquartered in Kelowna, Canada.